Is complete mesocolic excision oncologically superior to conventional surgery for colon cancer? A retrospective comparative study

Christos Agalianos a, Nikolaos Gouvas b, Christos Dervenis c, John Tsiaoussis d, George Theodoropoulos e, Demetrios Theodorou f, George Zografos e, Evaghelos Xynos f

Athens Naval & Veterans Hospital, Athens; Worcestershire Acute Hospitals Trust, UK; Konstantopouleio Hospital of Athens; School of Medicine, University of Crete; Hippokration Hospital, University of Athens; Creta Interclinic Hospital of Herakleion, Crete, Greece

Abstract

Background During the last decade, many efforts have been made in order to improve the oncologic outcomes following colonic resection. Complete mesocolic excision (CME) has proved to provide high rates of disease-free and overall survival rates in patients undergoing resection for colonic malignancies. The aim of our study was to further investigate the role of CME in colonic surgery through comparison with a series of conventional resections.

Methods All data regarding resections for colonic cancer since 2006 were obtained prospectively from two surgical departments. Retrieved data from 290 patients were analyzed and compared between those who underwent CME and those who had conventional surgery.

Results The CME group presented a higher rate of postoperative morbidity and readmissions. Histopathological features were in favor of CME surgery compared with the conventional group, in terms of both resected bowel length (33 vs. 20 cm) and lymph node harvest (27 vs. 18). Although CME was associated with better disease-free and overall survival times, only tumor differentiation, adjuvant chemotherapy and age had a statistically significant affect on those outcome values (P<0.05).

Conclusion CME improves histopathologic features, but without presenting oncologic superiority. Larger prospective studies following adequate surgical training are needed to prove the technique's advantages in oncologic outcomes.

Keywords Colon cancer, complete mesocolic excision, oncological outcomes

Ann Gastroenterol 2017; 30 (6): 688-696

Introduction

Total mesorectal excision for rectal cancer has resulted in excellent oncological outcomes, achieving lower rates of local recurrence and higher rates of both disease-free and overall survival rates, because all possible routes of spread are removed in a package, through dissection along well-defined embryological planes [1-3]. Hohenberger et al [4] thought that the same principles could be also applied to colon cancer surgery, by introducing the concept of complete mesocolic excision (CME). CME involves sharp dissection of the mesocolon along the embryological planes and high ligation and division of the vessels supplying blood to the colonic segment to be removed. By this technique, the removed colonic specimen should be covered by an intact mesocolic fascia and peritoneum, which, as a package, contains the...
tumor-bearing colonic segment and the mesocolon, with draining lymphatics, lymph nodes and possible tumor micro-

Many studies document clearly that CME results in more tissue being obtained in terms of the number of harvested lymph nodes, the distance from high tie to tumor and the surface of removed mesocolon, compared to conventional surgery [4-11]. However, the concept of CME remains controversial, with low uptake worldwide [6,12], mostly because the improved morphological features attributed to CME fail to translate into improved oncological outcomes. Observational studies [4,8,11] show that CME is associated with higher overall survival rate compared to historical series of patients after conventional surgery. More recently, there are comparative, population based studies demonstrating higher overall [12,13] and disease-free [12-14] survival rates after CME compared to conventional surgery, in particular for stage I and II right colon cancers.

The present comparative study aims to add further information based on the aforementioned principles; namely, management of patients under the control of multidisciplinary teams that follow the same guidelines for treatment and macroscopic, microscopic and histopathological assessment of the resected specimen based on the same rules.

**Patients and methods**

**Patients**

Adult patients (18 years old or older) from two surgical units were included. All colon cancer patients undergoing surgery were registered in a prospective electronic database. All patients who underwent surgery for colon cancer (lower border of tumor no less than 15 cm from the anal verge as measured by colonoscopy) from October 2006 to December 2011 were included in this study. All patients had histologically-proven adenocarcinoma of the colon and were staged by computed tomography (CT) scans. Exclusion criteria included synchronous metastatic disease and patients undergoing emergency surgery. All CME operations were performed or supervised by one specially trained surgeon (EX) in colorectal surgery. All other surgeons in the two units performed conventional colectomies, but all of them were equally experienced general surgeons with a special interest in colorectal surgery. All operations were performed by the open approach. All patients in the two units were enrolled postoperatively and managed within an enhanced recovery protocol. All CME specimens were freshly photographed and evaluated macroscopically and morphometrically using special software (Adobe Photoshop CS6), using the technique and standard definitions of the pathologists in Leeds, UK [11]. Two specially trained and experienced pathologists (KP, MK) evaluated all specimens from both groups histologically.

**Surgical techniques**

In left colectomy the procedure commenced by dissecting laterally to medially the embryological plane between the visceral and the parietal layer of Toldt's fascia. The left colon was mobilized in this way from the left paracolic gutter. The inferior mesenteric artery was then ligated and transected approximately 1 cm after its take-off from the aorta, so as to preserve the hypogastric nerve plexus, after which the inferior mesenteric vein was ligated and transected immediately below the inferior border of the pancreas. Dissection extended caudally over the promontory and to the upper “holy plane” and superiorly to the entry of the lesser epiploic sac, after division of the root of the left transverse mesocolon at the lower border of the pancreas. The sigmoid colon was excised in all cases, and a descending colon to mid or upper rectum anastomosis was fashioned using a circular stapler.

In right colectomy, the procedure started with a lateral-

**Follow up**

Chemotherapy was offered to all stage III patients by the Multidisciplinary Team as standard treatment in the form of mFOLFOX6. Stage II patients received adjuvant chemo only if histological and/or clinical adverse features were present, such as invasion of blood vessels or lymphatics, poor differentiation, perineural invasion, number of retrieved lymph nodes below 12, pT4 tumors and tumors causing obstruction. Furthermore, every stage II patient after 2009 without the above adverse pathologic features was tested for microsatellite
instability; if the tumor displayed microsatellite stability the patient was offered adjuvant chemotherapy. All patients were followed according to the international guidelines for patients with colon cancer. The date of last follow up was considered the date of the last chest and abdomen CT scan or the date of any additional test used to identify possible recurrence.

Statistical analysis

Nominal variables are presented using frequencies and percentages, whereas continuous variables are presented as median and interquartile range (normality was tested and did not hold).

The $\chi^2$ test for independence was used to evaluate associations between the procedure group and patients' characteristics. Kaplan-Meier survival analysis was performed in order to evaluate differences in the disease-free survival time and overall survival between the two procedure groups with the use of a log-rank test. Lastly, Cox regression was performed in order to identify factors independently related to the patients' disease-free and overall survival time. The factors entered into the model were those that were statistically significant in the univariate log-rank tests. Results are presented as hazard ratios and 95% confidence intervals (CI).

The criterion of statistical significance was $\alpha=5\%$. All statistical analyses were performed using of Stata SE version 11.1 (StataCorp. 2009, Texas, USA).

Results

Demographics, intraoperative and postoperative outcomes

Two hundred ninety patients were eligible for analysis. Table 1 shows the patients' demographics, preoperative tumor characteristics and types of operation performed. Apart from age, no other statistically significant difference was identified between the two groups.

There were no differences between the two groups as far as intraoperative events are concerned. Overall intraoperative complications ($P=0.652$), and in particular intraoperative bleeding ($P=0.156$) and failure of anastomosis ($P=0.081$), showed no difference between the two groups. Thirty-day mortality rates also did not differ between the groups. The CME group displayed significantly higher rates of postoperative morbidity ($P<0.001$), and when morbidity was further analyzed the CME group had higher rates of chest infection (31 vs. 0 patients, $P<0.001$) and postoperative ileus (31 vs. 7 patients, $P<0.001$). Furthermore, there were significantly more readmissions in the CME group (6 vs. 0 patients, $P=0.013$) whereas reoperation rates, bleeding, leak rates and postoperative ileus cases did not differ between the groups. Although there were more readmissions in the CME group, total hospital stay was significantly shorter when compared to the non-CME group (6 [4-8] vs. 7 [6-8] days, $P<0.001$). All readmissions (n=6) in the CME group were due to prolonged postoperative ileus.

Histopathological and oncological outcomes

Table 2 presents the association between the procedure groups and histopathological and oncological outcomes. The CME group had a significantly lower number of patients who were offered adjuvant chemotherapy ($P=0.012$), possibly because it included a significantly lower number of patients.

### Table 1 Patients and tumor characteristics in the two groups

| Characteristics   | Non-CME (n=145) | CME (n=145) | P-value |
|-------------------|-----------------|-------------|---------|
| Age               | 72 (65-78)*     | 68 (58-75)* | <0.001  |
| Sex               |                 |             |         |
| Male              | 79 (54.48%)     | 88 (60.69%) | 0.285   |
| Female            | 66 (45.52%)     | 57 (39.31%) |         |
| Tumor location    |                 |             |         |
| Cecum - ascending | 55 (39.57%)     | 42 (29.17%) | 0.219   |
| Hepatic flexure - transverse | 16 (11.51%) | 25 (17.36%) |         |
| Descending - upper sigmoid | 17 (12.23%) | 22 (15.28%) |         |
| Sigmoid - rectosigmoid | 51 (36.69%) | 55 (38.19%) |         |
| Localization      |                 |             |         |
| Right             | 71 (48.97%)     | 68 (46.90%) | 0.724   |
| Left              | 74 (51.03%)     | 77 (53.10%) |         |

*Presented as median (interquartile range)

CME, complete mesocolic excision

### Table 2 Histopathological and oncological data

| Variable                  | Non-CME (n=145) | CME (n=145) | P-value |
|---------------------------|-----------------|-------------|---------|
| CME grading               |                 |             |         |
| Mesocolic                 | -               | 135 (93.1%) |         |
| Intramesocolic            | -               | 10 (6.9%)   |         |
| Muscularis                | -               | 0 (0%)      |         |
| Differentiation           |                 |             |         |
| Low                       | 29 (20.00%)     | 38 (26.210%)| 0.210   |
| High                      | 116 (80.00%)    | 107 (73.79%)|         |
| Adjuvant Chemotherapy     |                 |             |         |
| No                        | 66 (46.48%)     | 87 (61.27%) | 0.012   |
| Yes                       | 76 (53.53%)     | 55 (38.73%) |         |

(Contd...)
patients who had CME had a longer resected bowel (median 33 vs. 20 cm) and more lymph nodes retrieved (median 27) than patients without CME (median 18).

### Survival analysis

Five-year disease-free survival was 84.6% (95%CI 76.9-89.9%) after CME and 76.4% (95%CI 67.1-83.4%) after non-CME (Fig. 1). In general, CME did not statistically significantly improve disease-free survival, but a longer disease-free survival time was observed for patients after CME than after non-CME (mean survival time 54.5 vs. 51.7 months, P=0.118).

With respect to overall survival, CME procedure improved the survival time significantly (P=0.014, Fig. 1). Patients with CME had longer overall survival times than those without CME (mean survival time 56.6 vs. 51.7 months). Five-year overall survival was 81.3% (95%CI 72.1-87.7%) after CME and 70.9% (95%CI 61.2-78.7%) after non-CME.

Stratified survival analysis to explore the association between treatment groups and disease-free survival time in subgroups (Table 3) showed a statistically significant association...
Table 3 Stratified associations between treatment group and survival time

| Associations         | Non-CME | CME | Log-rank |
|----------------------|---------|-----|----------|
|                      | Mean (95% CI) | Mean (95% CI) | P-value |
| Disease-free survival |         |     |          |
| By stage             |         |     |          |
| Stage I              | 60      | 60  | -        |
| Stage II             | 56.5 (53.6-59.8) | 58.2 (55.7-60.6) | 0.347 |
| Stage III            | 45.4 (40-50.7) | 44.7 (39.1-50.4) | 0.874 |
| By differentiation   |         |     |          |
| Low                  | 50.1 (42.5-57.8) | 48.2 (42.7-53.8) | 0.853 |
| High                 | 52.2 (49-55.4) | 57.1 (54.9-59.2) | 0.013 |
| By localization      |         |     |          |
| Right                | 51.1 (46.6-55.5) | 54.8 (51.5-58.2) | 0.131 |
| Left                 | 52.3 (48.4-56.3) | 54.3 (51.2-57.5) | 0.553 |
| Overall survival     |         |     |          |
| By stage             |         |     |          |
| Stage I              | 60      | 60  | -        |
| Stage II             | 53.7 (50.2-57.3) | 57.7 (55.3-60.1) | 0.157 |
| Stage III            | 47.9 (43.5-52.4) | 51.5 (47.8-55.3) | 0.673 |
| By differentiation   |         |     |          |
| Low                  | 49.9 (43.2-56.5) | 53.7 (50.2-57) | 0.920 |
| High                 | 52.2 (49.2-55) | 57.9 (56.4-59.6) | <0.001 |
| By localization      |         |     |          |
| Right                | 51.2 (47.2-55.2) | 55.7 (52.8-58.6) | 0.108 |
| Left                 | 52.2 (48.6-55.7) | 57.4 (55.9-58.9) | 0.071 |

Discussion

The concept of CME with central vascular ligation (CVL) has received very strong criticism. The initial criticism questioned the novelty of the technique. Many maintained that it was a concept already implemented by the majority of colorectal surgeons, in particular for tumors of the left colon [15,16]. In addition, the issue was raised of the reproducibility of the technique, because of the high level of surgical expertise required, along with concerns about higher rates of morbidity and intraoperative life-threatening adverse events. Many experienced and skillful colorectal surgeons claimed that some steps of CME with CVL, as described by Hohenberger et al [4], were technically very demanding, some were unnecessary, and because of that the technique was rendered very difficult to teach and to reproduce [13,17-19].

Our study failed to identify CME as an independent predictive factor for better disease-free and overall survival rates when compared with conventional colectomy, even when the disease was stratified by stage. Although survival analysis of the entire groups revealed a statistically significant difference favoring the CME group only as far as overall survival was concerned, when the cohort was stratified by several confounders, such as age, adjuvant chemotherapy, tumor differentiation and CME, the only significant independent predictive factor for both disease-free and overall survival rates, especially for UICC stage III patients, was high differentiation of tumors, which was associated with a significantly better disease-free and overall survival rates in the CME group.

Because there was a significant difference between the percentages of different stages of the disease between the two groups, all analyses were stratified by stage in order to confront this important source of bias. Nevertheless, CME failed to be identified as an independent predictive factor for disease-free and overall survival rates. This finding strongly contradicts many studies in the current literature [4,8,11-14,20]. The most

for patients that had high differentiation. Among those who had high differentiation, patients who had undergone a CME procedure had longer disease-free survival time than those undergoing non-CME. Stratification by stage did not show any statistically significant difference between groups (Table 3, Fig. 2). Likewise, there was an interaction between CME and differentiation, as well as adjuvant chemotherapy, for the overall survival time. Among patients who had highly differentiated tumors, it was found that the CME procedure resulted in a longer overall survival time compared to those who had a non-CME procedure (mean 57.9 vs. 52.2 months, P<0.001). In terms of survival with reference to death from cancer, interaction was also observed between CME and differentiation (P=0.005).

Characteristics that could potentially affect the disease-free survival or the overall survival were tested with the log-rank test. It was observed that disease-free and overall survival were statistically associated with differentiation and stage (P<0.05). Patients diagnosed with stage III disease and with low differentiation had shorter overall survival time and disease-free survival time, as expected (Fig. 3, 4). Patients with stage II disease did not have statistically different disease-free survival time from patients with stage I disease, but overall survival did differ (P=0.051 for disease-free and P=0.003 for overall survival). Moreover, age was also associated with overall survival (P=0.001). No significant difference in disease-free or overall survival was detected for factors such as sex, localization, tumor location, approach, complications, number of lymph nodes retrieved, and hospital stay.

Multivariable Cox regression showed that CME is not an independent predictive factor for higher disease-free survival or overall survival (Table 4), since the hazard ratio was not statistically significant. Differentiation, adjuvant chemotherapy and age were shown to be statistically significant predictive factors for disease-free and overall survival rates (P<0.05). Stratified analysis by stage showed that there were no statistically significant factors associated with disease-free and overall survival rates for patients with stage II cancer. In contrast, for patients with stage III cancer, low differentiation was shown to be a statistically significant independent predictive factor for lower disease-free and overall survival rates.
recent report, by Merkel et al, identified the implementation of CME surgery as one of the most important factors that significantly affected the improvement in disease-free survival and overall survival rates [20]. This could be attributed to several reasons: i) most patients with stage III disease had adjuvant chemotherapy administered, which may affect lymph node metastasis and improve recurrence and survival rates, in this way reducing the absolute effect of CME on the oncological outcome of these patients; ii) as lymph nodes in the CVL region are dissected by CME, but not by conventional colectomy, an upstaging from stage II to stage III is expected to occur in the CME group, whereas in conventional colectomy apical lymph nodes may be missed, leading patients to be classified as stage II if lymph nodes in the vicinity of the tumor are skipped by metastasis; iii) if not meticulous, histopathological examination may miss micro-metastases in apical lymph nodes dissected by CME colectomy. In this case patients are classified as having stage I or II disease. In conventional colectomy such micro-metastases are missed, because apical nodes are not removed, and these patients are also classified as stage I or II disease; and iv) differences in follow-up methods and duration may explain differences in oncological outcomes. In this study all patients followed a strict follow-up schedule, as described in the methods section.

There have been major concerns about increased intraoperative and immediate postoperative morbidity and even mortality after CME colectomy with CVL. This has been attributed to the extent of mesocolic resection, particularly in colectomies involving the right and transverse colon, where CVL is carried out in the region of the superior mesenteric vessels, increasing the risk of vascular injury and injury of the sympathetic nerve plexus. However, all series of CME with CVL show very low mortality and acceptable morbidity rates, with limited intraoperative blood loss. Furthermore, two comparative studies [13,21] show no significant differences in morbidity, mortality or anastomotic leak rates between CME and conventional colectomy. In accordance with the current literature, in the present cohort of patients, no difference between the CME and the non-CME group could be identified regarding mortality, intraoperative complications or reoperation rates.

Our study is subject to many methodological limitations that are commonly found among all studies available in the literature concerning the same issue. Although CME
Figure 3 Disease-free survival time by characteristics
CI, confidence interval

Figure 4 Overall survival time by characteristics
CME, complete mesocolic excision; CI, confidence interval

Annals of Gastroenterology 30
with CVL is a very well standardized operation for tumors located in the cecum, ascending, descending, sigmoid and rectosigmoid colon, the oncological radicality needed for tumors located along the transverse colon, from the hepatic to the splenic flexure, is still an open matter and remains highly controversial, particularly in terms of the extent of lymphadenectomy. At present, in the literature there are a few studies including series of patients with transverse colon tumors who underwent CME with CVL, by either open or laparoscopic approach, but do not report on transverse colon cancers outcomes separately. In one study [22] there is a considerable incidence of metastases of the extramesocolic lymph node stations, which cannot be underestimated and argues in favor of radical lymph node excision in these regions. Unfortunately, in this study the number of true transverse colon adenocarcinomas is also very limited and the outcomes are not presented separately, but at least the cases are equally distributed between the two groups. A subgroup analysis on the basis of tumor location is therefore mandatory when reporting outcomes for CME plus CVL. Right-sided and transverse colon cancers constitute a different group of tumors, not only because of different biological behavior but also because colectomy in terms of CME differs hugely from the conventional. In this sense, tumor location along the colon is a significant confounder when all cases are being analyzed together. From this viewpoint, CME with CVL is expected to have a greater oncological impact on right and transverse colon cancers. Furthermore, although conventional colectomy for right-sided colonic tumors is even less standardized, conventional left-sided resections are closer to and sometimes coincide with the concept of CME with CVL, probably because they are less technically demanding, which renders them more feasible. It is easily conceivable that probably one or even two centimeters of difference in the CVL between the groups may be not enough to highlight an anticipated statistical difference.

In conclusion, there is strong evidence from this study that, when CME with CVL is performed, a larger amount of tissue, including a greater number of lymph nodes, is excised compared to conventional colectomy. A statistically significant benefit in overall survival was also observed, an outcome that is subject to several confounders such as age, high differentiation of tumors and adjuvant chemotherapy. CME surgery seems to benefit non-aggressive tumors (high differentiation) as far as both

| Table 4 Multivariate Cox regression model to estimate disease-free and overall survival rates |
|-----------------------------------------------|-----------------|-----------------|
| Variable                                      | Disease-free survival | Overall survival |
|                                               | HR (95%) | P-value | HR (95%) | P-value |
| CME                                           | 0.868 (0.476-1.584) | 0.646   | 0.764 (0.405-1.442)  | 0.406     |
| Differentiation (high)                        | 0.476 (0.261-0.866) | 0.015   | 0.441 (0.233-0.833)  | 0.012     |
| Adjuvant chemotherapy                         | 10.44 (4.084-26.689) | <0.001  | 14.324 (4.393-46.709) | <0.001    |
| Age                                           | 1.036 (1.003-1.070) | 0.033   | 1.041 (1.004-1.078)  | 0.029     |

| Stratified by stage |
|---------------------|
| Stage II            |
| CME                 | 0.532 (0.101-2.798) | 0.456   | 0.576 (0.105-3.169) | 0.526     |
| Differentiation (high) | 0.396 (0.086-1.817) | 0.234   | 0.706 (0.125-3.984) | 0.693     |
| Adjuvant chemotherapy | 2.858 (0.632-12.921) | 0.173   | 4.268 (0.773-23.562) | 0.096     |
| Age                 | 1.028 (0.952-1.110) | 0.483   | 1.059 (0.965-1.161) | 0.227     |
| Stage III           |
| CME                 | 0.979 (0.510-1.879) | 0.950   | 0.830 (0.145-1.659) | 0.598     |
| Differentiation (high) | 0.515 (0.216-1.015) | 0.050   | 0.457 (0.222-0.940) | 0.033     |
| Adjuvant chemotherapy | 3.606 (0.833-15.617) | 0.086   | 4.561 (0.606-34.335) | 0.141     |
| Age                 | 1.036 (0.996-1.079) | 0.081   | 1.042 (0.997-1.088) | 0.067     |

HR, hazard ratio; CME, complete mesocolic excision

**Summary Box**

**What is already known:**
- Complete mesocolic excision (CME) results in better quality specimens
- CME leads to increased disease-free survival
- CME is well standardized

**What the new findings are:**
- CME leads to increased lymph node harvesting
- CME improves overall survival in tumors with high differentiation
- CME does not increase postoperative complications
Acknowledgment

The authors would like to deeply thank Drs. Maria Kafousi and Kleio Papaparaskeva for their work and contribution to this work, as they were the two pathologists who examined all resected surgical specimens.

References

1. Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986;1:1479-1482.
2. Quirke P, Steele R, Monson J, et al; NCRI Colorectal Cancer Study Group. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: A prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009;373:821-828.
3. Wibe A, Møller B, Norstein J, et al; Norwegian Rectal Cancer Group. A national strategic change in treatment policy for rectal cancer—implementation of total mesorectal excision as routine treatment in Norway. A national audit. Dis Colon Rectum 2002;45:857-866.
4. Hohenberger W, Weber K, Matzel K, Papadopoulos T, Merkel S. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation—technical notes and outcome. Colorectal Dis 2009;11:354-364; discussion 364-365.
5. Gouvas N, Pechlivanides G, Zervakis N, Kafousi M, Xynos E. Complete mesocolic excision in colon cancer surgery: a comparison between open and laparoscopic approach. Colorectal Dis 2012;14:1357-1364.
6. Killeen S, Mannion M, Devaney A, Winter DC. Complete mesocolic resection and extended lymphadenectomy for colon cancer: a systematic review. Colorectal Dis 2014;16:577-594.
7. Kontovounios C, Kinross J, Tan E, Brown G, Rasheed S, Tekkis P. Complete mesocolic excision in colorectal cancer: a systematic review. Colorectal Dis 2015;17:7-16.
8. West NP, Hohenberger W, Weber K, Perrakis A, Finan PJ, Quirke P. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010;28:272-278.
9. West NP, Kennedy RH, Magro T, et al. Morphometric analysis and lymph node yield in laparoscopic complete mesocolic excision performed by supervised trainees. Br J Surg 2014;101:1460-1467.
10. West NP, Kobayashi H, Takahashi K, et al. Understanding optimal colonic cancer surgery: comparison of Japanese D3 resection and European complete mesocolic excision with central vascular ligation. J Clin Oncol 2012;30:1763-1769.
11. West NP, Morris EJ, Rotimi O, Cairns A, Finan PJ, Quirke P. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol 2008;9:857-865.
12. Rosenberg J, Fischer A, Haglind E; Scandinavian Surgical Outcomes Research Group. Current controversies in colorectal surgery: the way to resolve uncertainty and move forward. Colorectal Dis 2012;14:266-269.
13. Galizia G, Lieto E, De Vita F, et al. Is complete mesocolic excision with central vascular ligation safe and effective in the surgical treatment of right-sided colon cancers? A prospective study. Int J Colorectal Dis 2014;29:89-97.
14. Storli KE, Sendreen K, Furnes B, et al. Short term results of complete (D3) vs. standard (D2) mesenteric excision in colon cancer shows improved outcome of complete mesenteric excision in patients with TNM stages I-II. Tech Coloproctol 2014;18:557-564.
15. Hogan AM, Winter DC. Complete mesocolic excision—a marker of surgical quality? J Gastrointest Surg 2009;13:1889-1891.
16. Hogan AM, Winter DC. Complete mesocolic excision (CME): a “novel” concept? J Surg Oncol 2009;100:182-183.
17. Cho MS, Baek SJ, Hur H, et al. Modified complete mesocolic excision with central vascular ligation for the treatment of right-sided colon cancer: long-term outcomes and prognostic factors. Ann Surg 2015;261:708-715.
18. Gao ZD, Ye YJ, Yang XD, et al. Feasibility of complete mesocolic excision in elderly patients with colon cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2012;15:1023-1026.
19. Guo P, Ye YJ, Jiang KW, et al. Learning curve of complete mesocolic excision for colon cancer. Zhonghua Wei Chang Wai Ke Za Zhi 2012;15:28-31.
20. Merkel S, Weber K, Matzel KE, Agaimy A, Göhl J, Hohenberger W. Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision. Br J Surg 2016;103:1220-1229.
21. Bertelsen CA, Neuenschwander AU, Jansen JE, et al; Danish Colorectal Cancer Group. Disease-free survival after complete mesocolic excision compared with conventional colon cancer surgery: a retrospective, population-based study. Lancet Oncol 2015;16:161-168.
22. Perrakis A, Weber K, Merkel S, et al. Lymph node metastasis of carcinomas of transverse colon including flexures. Consideration of the extramesocolic lymph node stations. Int J Colorectal Dis 2014;29:1223-1229.